One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Accesshttps://doi.org/10.1182/blood-2023-182388
Copy DOI
Export
Save
Share
Cite Journal: Blood |  Publication Date: Nov 2, 2023 |
 Citations: 17 |
Affiliation: Washington University in St. Louis, AbbVie (United States), Memorial Sloan Kettering Cancer Center, University Hospital Carl Gustav Carus, University of California, San Francisco, University Medical Center Hamburg-Eppendorf, University of North Carolina at Chapel Hill, Wake Forest University, Mayo Clinic, Winneshiek Medical Center, Icahn School of Medicine at Mount Sinai, Medical College of Wisconsin
Updated Safety and Efficacy Results of Abbv-383, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in a First-in-Human Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
